CN105738630A - Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis - Google Patents
Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis Download PDFInfo
- Publication number
- CN105738630A CN105738630A CN201610086468.6A CN201610086468A CN105738630A CN 105738630 A CN105738630 A CN 105738630A CN 201610086468 A CN201610086468 A CN 201610086468A CN 105738630 A CN105738630 A CN 105738630A
- Authority
- CN
- China
- Prior art keywords
- rkip
- hepatic fibrosis
- expression
- medicine
- serine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
The invention discloses research on the action of serine-threonine Raf kinase inhibitor protein in medicine for treating immune hepatic fibrosis.The action mechanism of the RKIP in the immune hepatic fibrosis forming process is discussed for the first time, animal experiments and in-vitro cell experiments show that in the immune hepatic fibrosis forming process, activation of an Raf-1/MEK/ERK1,2 signal transduction pathway is closely related to protein expression decreasing and phosphorylation increasing of the RKIP, and the RKIP has the important regulating and controlling effect in the hepatic fibrosis generating mechanism.Therefore, the fact that the Raf-1/MEK/ERK1,2 signal transduction pathway is inhibited through RKIP overexpression is an important target of new medicine for treating the immune hepatic fibrosis.The serine-threonine Raf kinase inhibitor protein can be applied to preparation of the medicine for treating the immune hepatic fibrosis.
Description
Technical field
The present invention relates to serine/threonine kinase inhibition albumen (Raf kinase inhibitory protein, RKIP)
Purposes, specifically RKIP as drug target be marked on preparation treatment fibrosis medicine in application.
Background technology
Hepatic fibrosis is the pathological change being caused chronic hepatopathy to have by Different types of etiopathogenises, shows as liver inner cell characteristically
Excessively synthesized and the deposition of epimatrix (extracellu larmatrix, ECM).Multinomial research is had to confirm, hepatic stellate cell
(hepatic stellate cells, HSCs) is the key cellular constituents in process of hepatic fibrosis, is the master of ECM in liver
Want cell derived.It is now recognized that suppression HSCs activation is one of prevention the main path reversing hepatic fibrosis with propagation.
Recent study finds, Raf-1/MEK/ERK1, and 2 signal paths take part in the regulation and control of HSCs activation and propagation
Journey, close with the generation development relationship of hepatic fibrosis, the formation of hepatic fibrosis can be affected from many aspects.
Serine/threonine (Ser/Thr) kinase inhibition albumen (is called for short: Raf kinase inhibition albumen, English name: Raf kinase
Inhibitory protein, RKIP) it is phosphotidylethanolabinding binding protein (phosphatidylethanolamine
Binding protein, PEBP) important a member in family.This albumen is a kind of and Raf-1 interacts and suppresses Raf-1/
MEK/ERK1, the albumen of 2 signal paths, RKIP is also that discovery and Raf-1 play suppression in be combineding with each other the most in vivo
The protein molecular of effect, indicates that it is likely to be of important biological function.RKIP is exempting from as the inhibitive factor of signal path
Effect in epidemic disease hepatic fibrosis is still known few.
Summary of the invention
It is an object of the invention to research and develop serine/threonine kinase inhibition albumen RKIP and be marked on system as drug target
Application in standby treatment fibrosis medicine.
The present invention is experimentation based on inventor and completes.
(1) Raf kinase inhibition albumen Expression in immunologic liver injury induced rat process of hepatic fibrosis
Situation
By SD male rat with aseptic porcine blood serum induced synthesis fibrosis animal model, observational study RKIP, p-
The distribution in hepatic fibrosis different times hepatic tissue such as RKIP and express change, and Raf-1/MEK/ERK1, the work of 2 paths
The effect of change situation.Result shows, porcine blood serum is successfully, reproduced out Rat Liver Fibrosis Model, and this model is adjoint in forming process
The change of liver function mark, hepatocyte chronic inflammation cellular infiltration, liver rope arrangement disorder, portal area and central vein knot occur
Forming tissue thickening, hepatic tissue collagen fiber showed increased, the content of serological index HA, LN, COL-I, PC III raises simultaneously.
Use SABC detection hepatic tissue RKIP, ERK and phosphorylated protein express, RT-PCR check RKIP, ERK,
The expression of Col-I and Col-III mRNA, Western blot detection RKIP, ERK etc. and the expression of phosphorylated protein, result
Showing, in process of hepatic fibrosis, RKIP expression declines, and phosphorylation RKIP level raises simultaneously.Phosphorylation simultaneously
ERK, Raf-1, MEK-1 express substantially to be increased, and shows to there is Raf-1/MEK/ERK1 in hepatic fibrosis generating process, and 2 signals turn
The activation of guiding path.
(2) Raf kinase inhibition albumen activation HSCs in expression and phosphorylation level
Cell results shows, the rat HSCs's of IL-1 β stimulation group, Locostatin+ IL-1 β group and Locostatin group
ERK1 mrna expression amount significantly raises.The most aobvious through the expressing quantity of RKIP, ERK, p-ERK of the HSCs of IL-1 β effect 48h
Write and raise, be remarkably decreased through the RKIP expressing quantity of the HSCs of Locostatin effect 48h, and the albumen of p-ERK, α-SMA
Expression significantly raises, and result above is pointed out, and RKIP expression after Locostatin suppresses declines, Raf-1/MEK/ ERK1,
2 signal transduction pathways are activated and promote the activation of HSCs, propagation.
In a word, RKIP effect in treatment immunologic liver injury, hepatic fibrosis is studied by the present invention first, real
Testing and show, in process of hepatic fibrosis, RKIP expression declines and phosphorylation RKIP level raises and Raf-1/MEK/
ERK1, the activation of 2 signal transduction pathways is closely related, raises RKIP level and hepatic fibrosis can be suppressed to develop, thus be medicine
The important target of thing treatment hepatic fibrosis.Serine/threonine kinase inhibition albumen can be applicable to preparation treatment fibrosis
Medicine in.
Detailed description of the invention
Experimental program:
(1), RKIP Expression situation in immunologic liver injury induced rat process of hepatic fibrosis
(1) experimental animal model preparation, be grouped and process
SD male rat 88, body weight is (140 ± 20) g, is divided into Normal group 28, model group 60.Normal group
Intraperitoneal injection of saline 0.5mL/, twice a week.Model group with aseptic porcine blood serum lumbar injection 0.5mL/ only, weekly 2
Secondary, totally 18 weeks, replicate Rat Liver Fibrosis Model.Model group rats is randomly selected respectively at 8wk, 11wk, 14wk, 18wk
15, normal rats 7, pull out after eyeball takes blood and put to death rat, and aseptic condition cuts skin and enters abdominal cavity, leaves and takes lobus sinister immediately
Hepatic tissue is in-80 DEG C of preservations, then cuts partial liver lobus sinister and fix with 4% paraformaldehyde, for future use.Hepatic tissue is taken from liver
The same area of lobus sinister.
(2) Testing index
1. automatic clinical chemistry analyzer detection Serum ALT, AST.
2. ELISA kit detection serum I Collagen Type VI (COL-I), III procollagen type (PC III), hyaluronic acid (HA), layer
Fibronectin (LN).
3. ELISA kit detection hepatic tissue III procollagen type (PC III), laminin，LN (LN).
4. HE dyeing: paraffin-embedded hepatic tissue is with the thickness serial section of 5 μm, and experimental procedure contaminates routinely
Color.
5. Masson trichrome stain: hepatic tissue is with 5 μm thickness serial section, and experimental procedure dyes routinely.
6. Immunohistochemical detection: the expression of RKIP, p-RKIP, p-ERK1/2, ERK1/2.
7. RT-PCR measures RKIP mRNA, COL-I mRNA, COL-III mRNA, ERK1 mRNA, ERK2 mRNA
Expression.
8. Western blot method detection RKIP, p-RKIP, p-ERK1/2, ERK1/2, COL-I, COL-III, α-SMA,
The expression of MEK, p-MEK.
(3) experimental result:
1. the change of rat vital sign, liver index
Normal group and the model group rats mental status are all good, hair smoothing, and activity and diet amount of drinking water are normal, and body weight increases
Long no difference of science of statistics.Starting at the end of experiment from experiment, Normal group and model group rats are all without dead.When dissected can
Seeing that model group rats liver occurs a certain degree of enlargement, hypertrophy, compared with Normal group, model group rats liver index increases
Greatly (p ＜ 0.05).The results are shown in Table 1-1.
The change (± s) of table 1-1 fibrosis rat liver index
Note: compare with Normal group, * P < 0.05, * * P < 0.01
2. the pathological change of fibrosis rat liver tissue
HE coloration result shows, normal rats lobules of liver clear in structure and complete, centered by central vein, to surrounding in putting
Penetrating shape arrangement, hepatocyte has no degeneration or necrosis.Chronic inflammation cellular infiltration seen from model group hepatocyte, liver rope arrangement disorder, with
Modeling time lengthening portal area and central vein connective tissue are thickening, form thick fibre gap, separate liver parenchyma in lobule
Or lobule, form the pseudolobuli differed in size.
Masson coloration result shows, has a small amount of blue collagen expression around rats in normal control group hepatic tissue blood vessel.Mould
Type control rats hepatic tissue collagen fiber showed increased, blue collagen is positioned at around portal area and blood vessel more and stretches out,
Connecting and form thicker fibrous septum, hepatocyte is in enlargement in various degree, and kytoplasm loosens.
3. the changes of contents of fibrosis rat blood serum HA, LN, COL-I, PC III
Result shows, the content of model group rats serum HA, LN, COL-I, PC III is all remarkably higher than normal rats (p ＜ 0.05
Or p ＜ 0.01).The results are shown in Table 1-2.
The changes of contents (± s) of table 1-2 fibrosis rat blood serum HA, LN, COL-I, PC III
Note: compare with Normal group, * P < 0.05, * * P < 0.01
4. on liver tissues of rats with hepatic fibrosis LN, PC III impact of content
Result shows, model group rats hepatic tissue PC III content is higher than normal rats, and along with the prolongation of modeling time, content is protected
Hold in level relatively smoothly；And the content of hepatic tissue LN was significantly higher than normal group at the 8th, 11 weeks, the results are shown in Table 1-3.
The changes of contents (± s) of table 1-3 rat with liver fibrosis LN, PC III
Note: compare with Normal group, * P < 0.05, * * P < 0.01
5. the phosphorylation level of immunohistochemical method detection RKIP and ERK
Immunohistochemical method testing result shows, in normal rats hepatic tissue, RKIP expression is higher, model group rats
In liver, RKIP positive cell significantly reduces；P-RKIP is relatively low at the expression of normal rat hepatic tissue, with modeling time lengthening,
In model group rats liver, p-RKIP expresses and strengthens；Normal rat hepatic tissue less expression ERK and p-ERK, and model group rats
In hepatic tissue, the expression of ERK and p-ERK higher (p ＜ 0.05 or p ＜ 0.01), is distributed mainly on around portal area and vein,
And along with the prolongation of modeling time, the expression of ERK and p-ERK is increasing trend, and statistical result is as shown in table 1-4.
The changes of contents of table 1-4 rat with liver fibrosis RKIP, p-RKIP, ERK1/2, p-ERK1/2
(± s)
Note: compare with Normal group, * P < 0.05, * * P < 0.01
6. fibrosis rat tissue RKIP mRNA, COL-I mRNA, COL-III mRNA, ERK1 mRNA, ERK2
The expression change of mRNA
RT-PCR testing result shows, in model group rats hepatic tissue, RKIP mrna expression fall occurs with the prolongation of modeling time
Low trend, the expression of ERK1 mRNA and ERK2 mRNA is in rising trend with modeling time lengthening, COL-I mRNA, COL-III
The expression of mRNA is significantly higher than normal group, and result is as shown in tables 1 to 5.
Table 1-5 immunity liver tissues of rats RKIPmRNA, ERK1mRNA, ERK2mRNA, COL-I mRNA, COL-III
The Expression (± s, n=8) of mRNA
Note: compare with Normal group, * P < 0.05, * * P < 0.01
7. Western blot method detection RKIP and Raf-1/MEK/ERK1,2 signal path associated protein and phosphorylation water thereof
Flat
Western blot method testing result shows, RKIP expression in normal rats hepatic tissue is higher, and model group is big
In rat liver, RKIP expression reduces；ERK expression in normal liver tissue is less, and in model group, ERK expresses and increases；p-
ERK expression in normal rats hepatic tissue is less, and with the prolongation of modeling time, in model group, the expression of p-ERK first rises
Downward trend occurs after height；With the prolongation of modeling time, the expression of Raf is on a declining curve, and p-Raf is in rising trend；
The expression in normal group of MEK is higher, downward trend occurs with the prolongation of modeling time, and the expression of p-MEK is then presented
The trend of liter；COL-I, COL-III, the expression of α-SMA rise (p ＜ 0.05 or p ＜ 0.01) with the prolongation of modeling time.Knot
Fruit is as shown in table 1-6 ~ 1-8.
The Expression (± s, n=8) of table 1-6 fibrosis rat RKIP, ERK, Raf, MEK albumen
Note: compare with Normal group, * P < 0.05, * * P < 0.01
Table 1-7 fibrosis rat COL-I, COL-III, the Expression (± s, n=8) of α-SMA albumen
Note: compare with Normal group, * P < 0.05, * * P < 0.01
The Expression (± s, n=8) of table 1-8 fibrosis rat p-RKIP, p-ERK, p-Raf, p-MEK albumen
Note: compare with Normal group, * P < 0.05, * * P < 0.01
(2), RKIP activation HSCs in expression and phosphorylation level
(1) experimental technique and Testing index
1. extract separation rat primary hepatic stellate cell successfully cultivate and pass on, and do following relevant identification experiment:
Platform expects blue dyeing, observation of cell survival rate；The autofluorescence of application fluorescence microscope HSCs；Activating cell is identified:
Hepatic stellate cell and the cultivation hepatic stellate cell α-SMA of more than 8 days that immunocytochemical stain detection has just separated dye.
The impact of the rat HSCs propagation that 2. IL-1 β is stimulated by MTT method detection Locostatin
3. RKIP between the hepatic stellate cell of the specific inhibitor Locostatin effect that RT-PCR measures use RKIP
MRNA, ERK1 mRNA, COL-I mRNA, COL-III mrna expression amount.
4. Western blot experiment detection IL-1 β is with the hepatic stellate cell of time excessive activation, and uses simultaneously
RKIP, ERK, p-ERK, COL-I, COL-III and α expression of-SMA albumen between the hepatic stellate cell of Locostatin effect
(2) experimental result:
1. the impact that rat HSCs is bred by MTT method detection IL-1 β and Locostatin
MTT method test experience result shows, compares with normal group, and the cell proliferation rate using IL-1 β stimulation group is 80.2%,
The cell proliferation rate of Locostatin+IL-1 β group is 25.1%, and the cell proliferation rate of Locostatin group is 7.7%.
2. the Locostatin impact on cultured rat hepatic stellate cells ERK signal path related gene expression
RT-PCR method testing result shows, compares with normal group, use IL-1 β stimulation group, Locostatin+IL-1 β group and
The expression no difference of science of statistics of the RKIP mRNA of the rat HSCs of Locostatin group, and ERK1 mRNA, COL-I
MRNA, COL-III mrna expression amount significantly raise (p ＜ 0.05 or p ＜ 0.01).Result is as shown in table 2-1.
Table 2-1. cultured rat hepatic stellate cells RKIPmRNA, ERK1mRNA, COL-1mRNA, COL-III impact of mrna expression
(2-△△CtMethod) (± s)
Note: compare with blank group, * P < 0.05, * * P < 0.01
3. the Locostatin impact on cultured rat hepatic stellate cells signal path correlative protein expression
Western blot testing result shows, compares with normal group, through RKIP, ERK, p-of the HSCs of IL-1 β effect 48h
ERK and COL-I, the expressing quantity of COL-III significantly raise, through Locostatin effect 48h HSCs RKIP,
COL-I, COL-III expressing quantity be remarkably decreased, and the expressing quantity of p-ERK, α-SMA significantly raises, through Locostatin
The expressing quantity of the RKIP acting on the HSCs of 47 h after effect 1h through IL-1 β is remarkably decreased, and the expressing quantity of p-ERK shows
Write and raise (p ＜ 0.05 or p ＜ 0.01).Result is as shown in table 2-2,2-3.
The expression (± s) of table 2-2. cultured rat hepatic stellate cells RKIP, ERK, p-ERK albumen
Note: compare with blank group, * P < 0.05, * * P < 0.01
Table 2-3. cultured rat hepatic stellate cells COL-I, COL-III, the expression (± s) of α-SMA albumen
Note: compare with blank group, * P < 0.05, * * P < 0.01.
Claims (2)
1. serine/threonine kinase inhibition albumen application in treatment fibrosis.
2. serine/threonine kinase inhibition albumen is marked on answering in preparation treatment fibrosis medicine as drug target
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610086468.6A CN105738630A (en) | 2016-02-16 | 2016-02-16 | Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610086468.6A CN105738630A (en) | 2016-02-16 | 2016-02-16 | Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105738630A true CN105738630A (en) | 2016-07-06 |
Family
ID=56245113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610086468.6A Pending CN105738630A (en) | 2016-02-16 | 2016-02-16 | Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105738630A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617369A (en) * | 2016-02-17 | 2016-06-01 | 林兴 | Application of serine/threonine Raf kinase inhibitory protein to medicines for treatment of chemical liver fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011502A2 (en) * | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| CN1759320A (en) * | 2003-01-14 | 2006-04-12 | Vib研究所 | A serum marker for measuring liver fibrosis |
-
2016
- 2016-02-16 CN CN201610086468.6A patent/CN105738630A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011502A2 (en) * | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| CN1759320A (en) * | 2003-01-14 | 2006-04-12 | Vib研究所 | A serum marker for measuring liver fibrosis |
Non-Patent Citations (3)
| Title |
|---|
| 马俊骥，等: "RKIP在胆总管结扎肝纤维化大鼠肝脏组织的表达", 《中国老年学杂志》 * |
| 马俊骥，等: "RKIP过表达对肝星状细胞在细胞外基质上黏附的抑制", 《世界华人消化杂志》 * |
| 马俊骥: "PKIP在大鼠肝纤维化发生机制中的作用研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617369A (en) * | 2016-02-17 | 2016-06-01 | 林兴 | Application of serine/threonine Raf kinase inhibitory protein to medicines for treatment of chemical liver fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | MCU Up‐regulation contributes to myocardial ischemia‐reperfusion Injury through calpain/OPA‐1–mediated mitochondrial fusion/mitophagy Inhibition | |
| Cao et al. | Mechanisms of endothelial to mesenchymal transition in the retina in diabetes | |
| Nakanishi et al. | Role of endoplasmic reticulum stress in light‐induced photoreceptor degeneration in mice | |
| Deng et al. | The neuroprotective effect of astaxanthin on pilocarpine-induced status epilepticus in rats | |
| Corrales et al. | Entrapment of conjunctival goblet cells by desiccation-induced cornification | |
| Chu et al. | Erythropoietin protects against hemorrhagic blood–brain barrier disruption through the effects of aquaporin-4 | |
| Braunger et al. | Identification of adult stem cells in Schwalbe's line region of the primate eye | |
| Yu et al. | Dexmedetomidine pretreatment attenuates kidney injury and oxidative stress during orthotopic autologous liver transplantation in rats | |
| Xu et al. | Organotypic culture of mouse meibomian gland: a novel model to study meibomian gland dysfunction in vitro | |
| Xu et al. | Efficacy of ethanol extract of Fructus lycii and its constituents lutein/zeaxanthin in protecting retinal pigment epithelium cells against oxidative stress: in vivo and in vitro models of age-related macular degeneration | |
| Bansode et al. | Cinnamon extract inhibits angiogenesis in zebrafish and human endothelial cells by suppressing VEGFR 1, VEGFR 2, and PKC‐mediated MAP kinase | |
| Qin et al. | Sirtuin 6 mitigated LPS‐induced human umbilical vein endothelial cells inflammatory responses through modulating nuclear factor erythroid 2‐related factor 2 | |
| CN106236740A (en) | A kind of change method and the application thereof that TRPC6 expresses in Oxytocin-immunoreactive Neurons | |
| CN105555363B (en) | Medical component and application thereof | |
| Chi et al. | Research on the role of GLP-2 in the central nervous system EPK signal transduction pathway of mice with vascular dementia | |
| Zhao et al. | Effect of lncRNA GAS5 on the apoptosis of neurons via the notch1 signaling pathway in rats with cerebral infarction. | |
| Chung et al. | YC‐1 rescues cancer cachexia by affecting lipolysis and adipogenesis | |
| Dai et al. | Protective activity of tert-butylhydroquinone against oxidative stress and apoptosis induced by glutamate agonizts in R28 cells and mice retina | |
| CN110075094A (en) | Pterostilbene is preparing the application in drug or health care product | |
| CN105738630A (en) | Application of serine-threonine Raf kinase inhibitor protein in preparation of medicine for treating immune hepatic fibrosis | |
| US20220079929A1 (en) | Use of axitinib and analogs thereof in preparing blood-brain barrier permeability regulator | |
| Wu et al. | Erythropoietin suppresses D-galactose-induced aging of rats via the PI3K/Akt/Nrf2-ARE pathway | |
| Zhao et al. | Arctigenin protects mice from thioglycollate‐induced acute peritonitis | |
| Miller et al. | Lactate treatment causes NF-κB activation and CD44 shedding in cultured trabecular meshwork cells | |
| Xu et al. | Tert-butyl hydroperoxide induces ferroptosis of bone mesenchymal stem cells by repressing the prominin2/BACH1/ROS axis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160706 |
|
| WD01 | Invention patent application deemed withdrawn after publication |